As the cell and gene therapy field transitions from the wild frontier into the industrial age, one of the key challenges ahead will be how to scale a therapeutic candidate efficiently and cost-effectively to meet patient population demand. This session will discuss insights from evaluating new technologies, to their implementation, and moving to high throughput manufacturing for taking advanced therapies from the clinic to the market.
Chair:
Matthew Hewitt, Ph.D., Vice President, Technical Officer Cell and Gene Therapy and Biologics, Charles River Laboratories
Speakers:
Lisa Deschamps, CEO and Executive Board Member, AviadoBio
Pedro Gonzalez-Alegre, M.D., Ph.D., Head of Gene Therapy Research, Spark Therapeutics
John Hadden, CEO and Co-founder, ViroCell Biologics
Sven Kili, M.D., CEO and Board Member, Antion Biosciences
